Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Interest Expenses (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Interest Expenses for 6 consecutive years, with $13000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest Expenses fell 23.53% year-over-year to $13000.0, compared with a TTM value of $50000.0 through Sep 2025, up 4.17%, and an annual FY2024 reading of $53000.0, up 89.29% over the prior year.
  • Interest Expenses was $13000.0 for Q3 2025 at Barinthus Biotherapeutics, up from $12000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $2.6 million in Q1 2021 and bottomed at $7000.0 in Q3 2023.
  • Average Interest Expenses over 5 years is $220076.9, with a median of $13000.0 recorded in 2025.
  • The sharpest move saw Interest Expenses crashed 99.32% in 2021, then surged 142.86% in 2024.
  • Year by year, Interest Expenses stood at $18000.0 in 2021, then soared by 311.11% to $74000.0 in 2022, then tumbled by 90.54% to $7000.0 in 2023, then surged by 71.43% to $12000.0 in 2024, then increased by 8.33% to $13000.0 in 2025.
  • Business Quant data shows Interest Expenses for BRNS at $13000.0 in Q3 2025, $12000.0 in Q2 2025, and $13000.0 in Q1 2025.